

18th May 2023

The General Manager,
Department of Corporate services
Bombay Stock Exchange Ltd (BSE)
Phiroze Jheejheebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Scrip Code - 543308 ISIN: INE967H01017 The Manager, Listing Department National Stock Exchange of India Limited,

Exchange Plaza, 5th Floor, Plot No.C/1, 'G' Block, Bandra - Kurla Complex, Mumbai - 400 051.

ISIN: INE967H01017

Symbol - KIMS

Dear Sir,

Sub: Investor presentation

Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find enclosed herewith the Investor Presentation on Audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Year ended 31st March 2023.

The said presentation is being uploaded on the website of the Company i.e., https://www.kimshospitals.com/investors/Disclosures under Regulation 46 of SEBI (LODR) Regulations, 2015/Analysts Calls schedule, PPT & Transcripts/PPT's / FY 22-23.

We request you to take this on record.

Thanking you, Yours truly,

For Krishna Institute of Medical Sciences Limited

MANTHA Digitally signed by MANTHA UMASHANKAR Date: 2023.05.18 18:29:38 +05'30'

Umashankar Mantha Company Secretary & Compliance Officer

Enclosed: As above





VISION:

To be the most preferred healthcare services brand by providing affordable care and best clinical outcomes to patients.


And to be the best place to work for doctors and employees.

OUR MISSION:

Provide affordable quality care to our patients with patient-centric systems and processes.

Enable clinical outcome-driven excellence by engaging modern medical technology.

Provide a strong impetus for doctors to pursue academics and medical research.



Affordable Quality Care
Best-in-Class Facilities
Patient Centric Systems & Processes

Clinical Outcome Driven Excellence
Latest Medical Technology
Strong Academics & Research Oriented

Enriching Atmosphere
Collaborative Culture
Growth Driven Career Approach

Transparent Governance
Strong Operational Performance
Consistent Growth



Multi Specialty Care

Brain

- Neurology
- Neurosurgery
- Psychiatry
- Neuro Rehabilitation

Heart

- Cardiology
- Cardiac Surgery
- Vascular Surgery
- Heart Transplant
- Cardio Rehabilitation

Lung

- Pulmonology
- Interventional Pulmonology
- Thoracic surgery
- Lung Transplant

ENT

- Ear
- Nose
- Throat
- Head and Neck Surgery

Eyes

Ophthalmology

Gastro Intestinal Tract

- Medical Gastroenterology
- Surgical Gastroenterology
- Hepatobiliary Pancreatic Surgery
- Liver Transplant
- Bariatric Surgery

Genito Urinary Tract

- Nephrology
- Urology
- Andrology
- Renal Transplant
- Gynecology
- Urogynecology
- IVF and ART
- Fetal Medicine
- Obstetrics

Oncology

- Medical Surgical and Radiation
- BMT and Hematology

Bones and Spine

- Orthopedics
- Arthroscopic Surgery
- Spine Surgery
- Ortho Rehabilitation

Skin

- Dermatology
- Cosmetology
- Plastic and Reconstructive Surgery

Orthodontics

Maxillo Facial Surgery

Anaesthesia

- OT Anaesthesia
- Day care Anaesthesia
- Pain Medicine

General Specialities

- Internal Medicine
- General Surgery
- Diabetology & Endocrinology

Pediatrics

- Pediatrics & Pediatric Sub Specialities
- Neonatology

Radiology

- Imaging
- Interventional Radiology

Lab Services

- Pathology
- Microbiology
- Biochemistry
- Molecular Biology
- Clinical Hematology

Critical Care Services

- ICU
- CTICU
- SICU
- NICU
- PICU
- Neuro ICU
- ECMO ICU
- Post Transplant ICU

Hospital Infection Control

Clinical Infectious Diseases

Private & Confidential




Maharashtra

Nagpur (334) **♀**

Karnataka

Bengaluru 💡 (Under Construction)



Telangana

- Secunderabad (1000)
- Paradise Circle (290)
- Gachibowli (237)

Andhra Pradesh


- Visakhapatnam (434)
- Srikakulam (200)
- Rajahmundry (195)
- Ongole (350)
- Kurnool (200)
- Nellore (250)
- Anantapur (250)

Map not to scale



Dr. B. Bhaskar Rao - Visionary Behind KIMS

Managing Director



A legend in CT Surgery, Dr. Bollineni Bhaskar Rao (MBBS, MS, DNB (CT Surgery)) is one of the very few Cardio-Thoracic Surgeons in the country, who performed over 30000 surgeries in his career spanning over more than 25 years.

Well known in the medical fraternity for his passion towards his profession, Dr. Rao started his entrepreneurial journey at "Mahavir Cardio Vascular Centre" in Hyderabad with 50 beds and performed heart surgeries at an unimaginable low cost of just Rs. 45,000 only. Dr. Rao never turned away any patient from the hospital for want of money.

The brand "Krishna Institute of Medical Sciences", under Dr. B. Bhaskar Rao's aegis began its journey in 2004 with a 300 bed hospital on par with the then established hospitals of Hyderabad in professional excellence, the state of art technology and infrastructure facilities.

Today KIMS is spread across 12 locations in Telangana, Andhra Pradesh and Maharashtra.

Dr. Bhaskar Rao was instrumental in formulating Rajiv Gandhi Aarogyasri scheme, first time launched in Andhra Pradesh in 2007 for providing health care to the poorest of the poor.

This prestigious scheme has won him accolades from all quarters of the country and the world. He was the chief architect of Aarogyashri scheme for both creating it and implementing it successfully.

This well formulated scheme has become so popular that the other States in India have emulated it time and again.



Dr. Abhinay Bollineni

Chief Executive Officer



Dr. Abhinay Bollineni joined KIMS Hospitals in 2013 and spent the next couple of years in Hospital Operations before taking charge of Strategy & Marketing for the Group in 2015.

In a short span of 5 years, KIMS expanded and opened five additional units (Kondapur, Vizag, Anantapur, Ongole, and Kurnool). Shortly after that, he was appointed as the CEO in 2019. The recent acquisitions led by him were of Sunshine Hospitals, Hyderabad and Kingsway Hospitals, Nagpur.

Dr. B. Abhinay completed MBBS from the Deccan Medical College, Hyderabad, in 2010. He was the lone qualified medical practitioner from India to be selected by the office of Hillary Clinton in 2011, where he participated in the 'International Visitor Leadership Program on Oncology: Research, Prevention and Treatment' held by the US Department of State

He was named in Business World's "BW 40 Under 40" list in 2019.

Under his stewardship, KIMS Hospitals got successfully listed on the Stock Exchanges in India in 2021.

Dr. Abhinay is passionate about using technology to enhance patient experience and clinical care. Towards this, he has spearheaded vital initiatives such as Financial counseling tool which uses AI to help patients with surgery costings among many others



Board of Directors



Dr. Bhaskara Rao Bollineni Managing Director



Dr. Abhinay Bollineni Chief Executive Officer



Mrs. Anitha Dandamudi Whole-time Director



Shantanu Rastogi Non-Executive Director



Mr. Rajeswara Rao G Independent Director, Chairman (Stakeholders' Relationship Committee)



Mr. Saumen Chakraborty
Independent Director,
Chairman (Audit Committee)



Mr. Pankaj Vaish Independent Director, Chairman (Nomination & Remuneration Committee)



Mr. Venkata Ramudu Jasthi Independent Director




Mr. Ratna Kishore Kaza Independent Director



Mrs. Y. Prameela Rani Independent Director



KIMS HOSPITALS[™] Shareholding Pattern - 31st March, 2023



Share Holder	No of Shares	Share Holding %	Category
Promoter	3,10,86,304	38.8%	
General Atlantica	68,89,147	8.6%	
ICICI Ventures	19,39,393	2.4%	
Mirae Asset MF	67,75,617	8.5%	DII
Axis MF	49,53,659	6.2%	DII
ICICI MF	26,28,348	3.3%	DII
Nomura	19,00,965	2.4%	FII
ICICI Life Insurance	17,74,591	2.2%	DII
Amansa Holdings Private Limited	16,15,302	2.0%	FII
Emerald Investments Limited	15,70,000	2.0%	FII
TATA AIA Life Insurance	14,58,407	1.8%	DII
HDFC Life Insurance	12,14,217	1.5%	DII
Vanguard Equity Funds	9,99,340	1.2%	FII



Modern Medical Technology



4-Arm HD da Vinci Robotic Surgical System

Facilitates complex surgeries that are virtually scar less



O-Arm Scanner

Multi-dimensional surgical imaging platform optimized for use in spine, orthopaedic, and trauma-related surgeries



Spy Glass

State of the art add on to ERCP that allows doctors to observe patients' biliary duct system and other tiny ducts in the pancreas



Fibroscan

Specialized non-invasive diagnostic ultrasound-based device that measures fibrosis and steatosis caused by different liver diseases



Novalis Tx Linear Accelerator

Machine used in radiosurgery and radiotherapy for treating cancer patients



3 Tesla MRI

Non-invasive diagnostic imaging technique performing faster scans and gives improved diagnostic sensitivity and specificity




Mako Robotic for Knee Replacement

Produces minimal blood loss and a smaller scar. Helps preserve healthy bone and soft tissue. Results in less post-operative pain than manual techniques.



Cuvis Ortho Robo

The most advanced surgical equipment capable of 3D pre-planning, virtual surgery and precise cutting to provide accurate and precise surgery results



EBUS

Used to diagnose lung cancer, infections, and other diseases causing enlarged lymph nodes in the chest



STEALTH STATION S8

Provides the Neuro surgeon to use data intraoperatively for advanced visualization.



IMPELLA

Impella, the world's smallest heart pump, is a percutaneous catheter-based technology that provides hemodynamic support to the heart



EVIS X1 Endoscopy System

The most advanced Endoscopy system helps improving clinical outcomes by providing Endoscopist with innovative and proven tools.

9



- First in Asia in to do Trans catheter Tricuspid Valve replacement procedure done in 2018
- Largest Joint replacement program in South Asia.
- One of the largest neuroscience programs for epilepsy among private hospitals in the country
- Largest ECMO program (18 machines) in the country.
- First hospital in Hyderabad to use an ECMO machine in 2013.
- First hospital in Hyderabad to do a Neonatal ECMO
- First in India to do TOF repair using CorMatrix patch for pulmonary valve reconstruction in 2017
- First in the country to do Robotic spleen preserving distal pancreatectomy

- India's first COVID Double Lung transplant done in 2020
- India's first Breathing Lung transplant done in 2021
- First hospital in South India to introduce Da Vinci Robotic System
- The first hospital in Andhra Pradesh and Telangana to have been Green OT certified in 2016
- First hospital in India to perform Arch Repair in Neonates and infants without TCA
- First Hospital in South India to do Total Skin Electron Beam Radiation therapy in 2018
- Number 1 player in Organ transplantation speciality (Heart, Lung, Liver and Kidney)*

- Number 1 in Nephrology treatments in Andhra Pradesh*
- Number 1 in Neurosurgery & Poly trauma treatments in Andhra Pradesh*
- Number 1 in Cardio related surgeries and treatments programs in Andhra Pradesh *
- Number 1 in Urology (Genito-Urinary) surgeries performed in Andhra Pradesh*



Key Accomplishments









Pharmacie De Qualite (PDQ)
Certification Overall PDQ Evaluation
Performance Score - 98%
Grading - PLATINUM



2nd Best Hospital in Hyderabad (2021 & 2022)



20th National Award for Excellence in Energy Management Award 2019



National Quality Excellence Awards 2019 for Best Super Specialty Hospital in Telangana













Consistent performer over 2 decades (Rupees in Millions)





Total Revenue *EBITDA

12

^{*}EBITDA before IND AS 116 and other income

^{**}Revenue and EBITDA are including 7 month performance (Sep'22 - Mar'23) of the newly acquired unit at Nagpur

^{***}FY22 EBITDA includes share of profit from JV (Sunshine)



Q4 FY23 Updates



Financial & Operational Highlights - 1/2 (Rupees in Millions)

FINANCIAL HIGHLIGHTS

Q4 FY 23 Consolidated

- Company achieved highest ever Consolidated Quarterly Revenue, EBITDA, PBT & PAT
- Consolidated Quarterly Revenue from Operations and EBITDA grew by 54.7% and 38.8%, respectively, on a YoY basis
- EBITDA Margin sequentially improved by 1.4% to 27.1% in Q4 FY 23 from 25.7% in Q3 FY 23; led by operational efficiency
- Consolidated Key Financials figures are as follows (Rs in Mn):

Dowtioulous		Consoldi	ated - FY23 Q	4 Results		Consoldiated - FY23 Results			
Particulars	Q4 FY 23	Q3 FY 23	Q4 FY 22	QoQ	YoY	FY 23	FY 22 16,710.9 202.6 16,508.3 4,473.4 160.3 726.7 5,360.5 202.6 35.4 5,122.4 31.0%	YoY	
Total Income	5,808.1	5,686.1	3,805.3			22,235.5	16,710.9		
Less : Other Income	48.9	64.5	81.9			258.8	202.6		
Revenue from Operations	5,759.2	5,621.6	3,723.4	2.4%	54.7%	21,976.7	16,508.3	33.1%	
PBT	1,272.7	1,128.1	992.7	12.8%	28.2%	4,700.8	4,473.4	5.1%	
Add : Interest	54.2	115.2	38.5			305.5	160.3		
Add : Depreciation	354.4	332.9	186.4			1,292.6	726.7		
Reported EBITDA (Including other income) as per Financials	1,681.3	1,576.2	1,217.6	6.7%	38.1%	6,298.8	5,360.5	17.5%	
Less : Other Income	48.9	64.5	81.9			258.8	202.6		
Less : INDAS 116	69.0	67.9	9.3			273.6	35.4		
EBITDA Pre INDAS & Other Income	1,563.3	1,443.8	1,126.4	8.3%	38.8%	5,766.4	5,122.4	12.6%	
EBITDA % to Revenue from Operations	27.1%	25.7%	30.3%			26.2%	31.0%		



Financial & Operational Highlights - 2/2

FINANCIAL HIGHLIGHTS

Q4 FY 23 Consolidated

- Consolidated Revenue from operations grew by 54.7% YoY basis and 2.4% on QoQ basis to Rs. 5,759.2 mn
- Consolidated EBITDA (Pre-INDAS and Other Income) grew by 38.8% on a YoY basis and 8.3% on a QoQ basis to Rs. 1563.3 mn
- Consolidated EBITDA Margin stands at 27.1% which has improved by 1.4% over the previous quarter; led by operational efficiency
- Consolidated PAT grew by 18.4% on a YoY basis and 20.6% on a QoQ basis to Rs. 986 mn
- Consolidated EPS grew by 15.6% on a YoY basis and 22.8% on a QoQ basis to Rs 11.7

OPERATIONAL HIGHLIGHTS

Q4 FY 23 Consolidated

• The ARPP and ARPOB registered improvements both on QoQ and YoY basis. The IP and OP volumes also displayed strong growth on YoY basis

Deutieuleus		F	Y23 Q4 Result	FY23 Results				
Particulars	Q4 FY23	Q3 FY23	Q4 FY22	QoQ	YoY	FY23	FY22	YoY
IP Volumes ('000)	45.1	45.8	32.6	-1.7%	38.3%	177.2	136.7	29.6%
OP Volumes ('000)	380.9	381.6	270.9	-0.2%	40.6%	1,462.4	1,013.8	44.3%
ARPOB (in. Rs)	30,573	29,812	25,144	2.6%	21.6%	29,946	25,323	18.3%
ARPP (in. Rs)	1,27,916	1,22,631	1,15,296	4.3%	10.9%	1,24,187	1,21,232	2.4%

PROJECT STATUS

- KIMS Sunshine Secunderabad Hospital is expected to be completely shifted to a new state-of-the-art facility by Q2 FY 24.
- Nashik (Greenfield project) and Bangalore (Semi Brownfield) are progressing well and are expected to be operational as per schedule.
- Vizag Gastro unit is ready and will be operational by Q1 FY 24.
- Thane project's legal documentation work is in progress and expected to be completed by June'23. The hospital is expected to be operational by Q2 FY 25.
- On the digital side, SAP has been successfully implemented and gone live at a few of our units and is expected to be fully implemented across all units by the end of FY 24.



Digital & ESG Initiatives

DIGITAL INITIATIVES

During the last quarter, KIMS continued its digitization journey with a goal of having 100% paperless business process in all its operational, clinical and finance verticals.

As part of this journey, last quarter we have either initiated or delivered the following programs:

- Delivered application process controls that enable automation, revenue controls and reduce human intervention
- Delivered EHR enhancements for OP, IP, ER and OT that digitizes all patient records as well as communication including prescription, lab results, transfers and cross consultations
- Rolled out Patient facing engagement application in Nagpur and Gachibowli.
- Continued AWS adoption for all global applications and SSO for access control.
- Went live with SAP for FICO, MM and SD in 4 units. Working on 5 units next.

ESG INITIATIVES

KIMS, Secunderabad has partnered up with Smart Joules Pvt Ltd (SJPL) a prominent Energy Services Company (ESCO) in 2018. A new and innovative model known as JoulePAYS was executed wherein, KIMS makes Zero Capital investment to implement various Energy Conservation Measures (ECMs) across the hospital and gets a guaranteed energy savings of minimum 10% annually over the baseline energy consumption.

For the period Jan 2023 – Mar 2023:


- 12.9 % of total energy consumption saved
- INR 39.63 lakhs of total energy cost saving achieved
- 139 tonnes CO2 saved


In real life translation, the above translates to approximately the following:


- 4,797 households getting electricity
- 5.62 Lakhs Kms less driven
- 5,699 trees planted




KIMS HOSPITALS™ Group Operating Performance - 1/3














KIMS HOSPITALSTM Group Operating Performance - 2/3 (Rupees in Millions)


TOTAL REVENUE







EBITDA*





18






Private & Confidential

^{*}EBITDA before IND AS 116 and other income

^{**}PBT and PAT are excluding items of:

¹⁾ Associates share of profit of Rs. 19.7 Mn and Rs. 75.4 Mn in FY22 Q3 & Q4 and FY22

²⁾ Fair value gain on aquisition of control of Rs. 148.3 Mn in Q2 FY23 and FY23



Particulars	FY21	FY22	FY23	Q1 FY23	Q2 FY23	Q3 FY23	Q4 FY23
Bed Capacity	3,064	3,064	3,940	3,666	4,015	4,015	3,940
Operational Beds	2,590	2,590	3,468	3,222	3,543	3,543	3,468
Census Beds	2,246	2,246	2,960	2,760	3,026	3,026	2,960
Non Census Beds	344	344	508	462	517	517	508
Occupied Beds	1,765	1,793	2,071	1,807	2,223	2,053	2,095
Occupancy	78.6%	79.8%	69.3%	65.5%	72.6%	68.2%	70.8%
IP volume	1,16,592	1,36,731	1,77,181	39,673	46,616	45,836	45,056
OP volume	8,30,211	10,13,759	14,62,439	3,24,797	3,75,188	3,81,604	3,80,850
ARPOB (Rs.)	20,609	25,323	29,946	30,192	29,237	29,812	30,573
ARPP (Rs.)	1,13,904	1,21,232	1,24,187	1,25,141	1,21,302	1,22,631	1,27,916
ALOS	5.5	4.8	4.1	4.1	4.1	4.1	4.2
Total Revenue (Rs. in Mn)	13,401	16,711	22,235	5,008	5,733	5,686	5,808
EBITDA* (Rs. in Mn)	3,672	5,122	5,766	1,312	1,447	1,444	1,563
EBITDA % to Total Revenue	27.4%	30.7%	25.9%	26.2%	25.2%	25.4%	26.9%
PBT** (Rs. in Mn)	2,790	4,473	4,701	1,074	1,226	1,128	1,273
PAT** (Rs. in Mn)	2,055	3,343	3,510	792	912	818	987

^{*}EBITDA before IND AS 116 and other income

19

^{**}PBT and PAT are excluding items of:

¹⁾ Associates share of profit of Rs. 19.7 Mn and Rs. 75.4 Mn in FY22 Q3 & Q4 and FY22

²⁾ Fair value gain on aquisition of control of Rs. 148.3 Mn in Q2 FY23 and FY23

Occupancy % based on operational Census Beds



Comparison of Telangana and Andhra Pradesh Matured Hospitals - 1/2

Particulars			Telangan	a (KIMS)				AP Matured Assets						
1 di tiodidi 3	FY21	FY22	Q1 FY 23	Q2 FY23	Q3 FY23	Q4 FY23	FY23	FY21	FY22	Q1 FY23	Q2 FY23	Q3 FY23	Q4 FY23	FY23
Bed Capacity	1,200	1,200	1,200	1,200	1,200	1,200	1,200	630	630	630	645	645	645	645
Operational Beds	1,035	1,035	1,065	1,085	1,085	1,085	1,085	580	580	580	595	595	595	595
Census Beds	856	856	886	906	906	906	906	515	515	515	530	530	530	530
Non Census Beds	179	179	179	179	179	179	179	65	65	65	65	65	65	65
Occupied Beds	586	642	656	668	614	639	644	413	405	356	411	408	407	396
Occupancy	68.5%	75.0%	74.1%	73.8%	67.8%	70.5%	71.5%	80.3%	78.7%	69.1%	77.6%	77.0%	76.8%	75.2%
IP volume	45,087	53,567	14,001	15,959	14,525	14,592	59,077	30,503	30,963	7,548	8,361	8,152	8,103	32,164
OP volume	3,31,709	4,35,663	1,29,229	1,43,885	1,42,178	1,45,644	5,60,936	2,09,178	1,94,429	49,017	53,313	51,027	51,120	2,04,477
ARPOB (Rs.)	39,571	46,745	42,581	46,310	47,872	49,838	46,601	13,608	15,194	16,901	16,465	16,442	16,825	16,648
ARPP (Rs.)	1,87,738	2,04,519	1,81,687	1,78,435	1,86,166	1,96,382	1,85,540	67,303	72,566	72,491	74,487	75,725	76,022	74,719
ALOS	4.7	4.4	4.3	3.9	3.9	3.9	4.00	4.9	4.8	4.3	4.5	4.6	4.5	4.5
Total Revenue (Rs. in Mn)	8,560	11,066	2,562	2,905	2,739	2,891	11,096	2,060	2,252	549	624	618	617	2,408
EBITDA* (Rs. in Mn)	2,705	3,987	790	844	833	1,016	3,483	518	554	177	200	194	182	753
EBITDA % to Total revenue	32%	36%	31%	29%	30%	35%	31%	25%	25%	32%	32%	31%	29%	31%

20

^{*}EBITDA before IND AS 116 and other income Intercompany eliminations and dormant units are adjusted in Telangana

¹⁾ Telangana - Secunderad and Kondapur

²⁾ AP Matured Assets - Nellore, Rajahmundry and Srikakulam



Comparison of Andhra Pradesh Acquired, Sunshine & Nagpur - 2/2

		AP A	Acquired Ass	sets					Sunshine				Nag	pur					Group			
FY21	FY22	Q1 FY23	Q2 FY23	Q3 FY23	Q4 FY23	FY23	Q1 FY23	Q2 FY23	Q3 FY23	Q4 FY23	FY23	Q2 FY23**	Q3 FY23	Q4 FY23	FY23	FY21	FY22	Q1 FY23	Q2 FY23	Q3 FY23	Q4 FY23	FY23
1234	1234	1234	1234	1234	1234	1234	602	602	602	527	527	334	334	334	334	3,064	3,064	3,666	4,015	4,015	3,940	3,940
975	975	975	1011	1011	1011	1011	602	602	602	527	527	250	250	250	250	2,590	2,590	3,222	3,543	3,543	3,468	3,468
875	875	875	911	911	911	911	484	484	484	418	418	195	195	195	195	2,246	2,246	2,760	3,026	3,026	2,960	2,960
100	100	100	100	100	100	100	118	118	118	109	109	55	55	55	55	344	344	462	517	517	508	508
766	746	603	758	723	760	711	191	206	171	165	182	179	137	124	137	1,765	1,793	1,807	2,223	2,053	2,095	2,071
87.5%	85.3%	69.0%	83.2%	79.3%	83.4%	78.8%	39.5%	42.6%	36.3%	39.6%	39.5%	92.0%	70.4%	63.4%	70.4%	78.6%	79.8%	65.5%	72.6%	68.2%	70.8%	69.3%
41,002	52,201	12,567	14,718	14,236	14,407	55,928	5,557	5,901	4,730	4,600	20,788	1,677	4,193	3,354	9,224	1,16,592	1,36,731	39,673	46,616	45,836	45,056	1,77,181
2,89,324	3,83,667	96,889	1,13,856	1,09,680	1,05,276	4,25,701	49,662	54,845	51,345	49,845	2,05,697	9,289	27,374	28,965	65,628	8,30,211	10,13,759	3,24,797	3,75,188	3,81,604	3,80,850	14,62,439
9,881	12,388	14,240	12,848	13,840	13,605	13,596	62,706	60,419	65,436	67,362	63,844	26,489	29,413	31,309	29,597	20,609	25,323	30,192	29,237	29,812	30,573	29,946
67,381	64,631	62,226	60,890	64,637	64,584	63,095	1,96,464	1,94,104	2,13,137	2,18,081	2,04,371	85,035	88,538	1,03,792	93,448	1,13,904	1,21,232	1,25,141	1,21,302	1,22,631	1,27,916	1,24,187
6.8	5.2	4.4	4.7	4.7	4.7	4.6	3.1	3.2	3.3	3.2	3.2	3.2	3.00	3.3	3.2	5.5	4.8	4.1	4.1	4.1	4.2	4.1
2,781	3,392	787	899	925	933	3,544	1,110	1,162	1,031	1,000	4,304	143	372	368	884	13,401	16,711	5,008	5,733	5,686	5,808	22,235
450	676	151	177	182	161	671	194	212	219	190	815	14	15	15	44	3,673	5,218	1,312	1,447	1,444	1,563	5,766
16%	20%	19%	20%	20%	17%	19%	17%	18%	21%	19%	19%	10%	4%	4%	5%	27%	31%	26%	25%	25%	27%	26%
	1234 975 875 100 766 87.5% 41,002 2,89,324 9,881 67,381 6.8 2,781 450	1234 1234 975 975 875 875 100 100 766 746 87.5% 85.3% 41,002 52,201 2,89,324 3,83,667 9,881 12,388 67,381 64,631 6.8 5.2 2,781 3,392 450 676	FY21 FY22 Q1 FY23 1234 1234 1234 975 975 975 875 875 875 100 100 100 766 746 603 87.5% 85.3% 69.0% 41,002 52,201 12,567 2,89,324 3,83,667 96,889 9,881 12,388 14,240 67,381 64,631 62,226 6.8 5.2 4.4 2,781 3,392 787 450 676 151	FY21 FY22 Q1 FY23 Q2 FY23 1234 1234 1234 1234 975 975 975 1011 875 875 875 911 100 100 100 100 766 746 603 758 87.5% 85.3% 69.0% 83.2% 41,002 52,201 12,567 14,718 2,89,324 3,83,667 96,889 1,13,856 9,881 12,388 14,240 12,848 67,381 64,631 62,226 60,890 6.8 5.2 4.4 4.7 2,781 3,392 787 899 450 676 151 177	1234 1234 1234 1234 1234 975 975 975 1011 1011 875 875 875 911 911 100 100 100 100 100 766 746 603 758 723 87.5% 85.3% 69.0% 83.2% 79.3% 41,002 52,201 12,567 14,718 14,236 2,89,324 3,83,667 96,889 1,13,856 1,09,680 9,881 12,388 14,240 12,848 13,840 67,381 64,631 62,226 60,890 64,637 6.8 5.2 4.4 4.7 4.7 2,781 3,392 787 899 925 450 676 151 177 182	FY21 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 1234 1234 1234 1234 1234 1234 975 975 975 1011 1011 1011 875 875 875 911 911 911 100 100 100 100 100 100 766 746 603 758 723 760 87.5% 85.3% 69.0% 83.2% 79.3% 83.4% 41,002 52,201 12,567 14,718 14,236 14,407 2,89,324 3,83,667 96,889 1,13,856 1,09,680 1,05,276 9,881 12,388 14,240 12,848 13,840 13,605 67,381 64,631 62,226 60,890 64,637 64,584 6.8 5.2 4.4 4.7 4.7 4.7 2,781 3,392 787 899 925 933 450	FY21 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 1234 1234 1234 1234 1234 1234 1234 1234 975 975 975 1011 1011 1011 1011 1011 875 875 911 911 911 911 911 100 100 100 100 100 100 100 766 746 603 758 723 760 711 87.5% 85.3% 69.0% 83.2% 79.3% 83.4% 78.8% 41,002 52,201 12,567 14,718 14,236 14,407 55,928 2,89,324 3,83,667 96,889 1,13,856 1,09,680 1,05,276 4,25,701 9,881 12,388 14,240 12,848 13,840 13,605 13,596 67,381 64,631 62,226 60,890 64,637 64,584 63,095 6.8	FY21 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 Q1 FY23 1234 1234 1234 1234 1234 1234 1234 602 975 975 975 1011 1011 1011 1011 602 875 875 875 911 911 911 911 911 484 100 100 100 100 100 100 100 118 766 746 603 758 723 760 711 191 87.5% 85.3% 69.0% 83.2% 79.3% 83.4% 78.8% 39.5% 41,002 52,201 12,567 14,718 14,236 14,407 55,928 5,557 2,89,324 3,83,667 96,889 1,13,856 1,09,680 1,05,276 4,25,701 49,662 9,881 12,388 14,240 12,848 13,840 13,605 13,596 62,706	FY21 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 Q1 FY23 Q2 FY23 1234 1234 1234 1234 1234 1234 1234 602 602 975 975 975 1011 1011 1011 1011 602 602 875 875 875 911 911 911 911 911 484 484 100 100 100 100 100 100 100 118 118 766 746 603 758 723 760 711 191 206 87.5% 85.3% 69.0% 83.2% 79.3% 83.4% 78.8% 39.5% 42.6% 41,002 52,201 12,567 14,718 14,236 14,407 55,928 5,557 5,901 2,89,324 3,83,667 96,889 1,13,856 1,09,680 1,05,276 4,25,701 49,662 54,845 9,881	FY21 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 Q1 FY23 Q2 FY23 Q3 FY23 1234 1234 1234 1234 1234 1234 602 602 602 975 975 975 1011 1011 1011 1011 602 602 602 875 875 875 911 911 911 911 484 484 484 100 100 100 100 100 118 118 118 766 746 603 758 723 760 711 191 206 171 87.5% 85.3% 69.0% 83.2% 79.3% 83.4% 78.8% 39.5% 42.6% 36.3% 41,002 52,201 12,567 14,718 14,236 14,407 55,928 5,557 5,901 4,730 2,89,324 3,83,667 96,889 1,13,856 1,09,680 1,05,276 4,25,701 <td>FY21 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 1234 1234 1234 1234 1234 1234 602 602 602 527 975 975 975 1011 1011 1011 1011 602 602 602 527 875 875 875 911 911 911 911 484 484 484 418 100 100 100 100 100 118 118 118 109 766 746 603 758 723 760 711 191 206 171 165 87.5% 85.3% 69.0% 83.2% 79.3% 83.4% 78.8% 39.5% 42.6% 36.3% 39.6% 41,002 52,201 12,567 14,718 14,236 14,407 55,928 5,557 5,901 4,730 4,600</td> <td>FY21 FY22 O1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 1234 1234 1234 1234 1234 1234 602 602 602 527 527 975 975 975 1011 1011 1011 1011 602 602 602 527 527 875 875 875 911 911 911 911 484 484 484 418 418 100 100 100 100 100 100 118 118 118 109 109 766 746 603 758 723 760 711 191 206 171 165 182 87.5% 85.3% 69.0% 83.2% 79.3% 83.4% 78.8% 39.5% 42.6% 36.3% 39.6% 39.5% 41,002 52,201 12,567 14,718 14</td> <td>FY21 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 Q2 FY23** Q3 FY23 Q4 FY23 FY23 Q2 FY23** Q2 FY23** Q4 FY23 PY23 Q2 FY23** Q3 FY23 Q4 FY23 FY23 Q2 FY23*** Q2 FY23*** Q4 FY23 PY23 Q2 FY23*** Q3 FY23 Q4 FY23 PY23 Q2 FY23*** Q3 FY23 Q4 FY23 PY23 Q2 FY23*** Q3 FY23 Q4 FY23 PY23 Q3 FY23 Q4 FY23** PY23 Q3 FY23 Q4 FY23** Q2 FY23*** Q2 FY23*** Q3 FY23 Q4 FY23*** PY23 Q3 FY23** Q4 FY23*** Q2 FY23*** Q3 FY23*** Q4 FY23*** Q4 FY23*** Q4 FY23*** PY23*** Q4 FY23*** Q4 FY23***<</td> <td>FY21 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 Q2 FY23* Q3 FY23 Q4 FY23 PY23 Q2 FY23** Q3 FY23** Q3 FY23** Q4 FY23 FY23 Q2 FY23** Q3 FY23** Q3 FY23** Q4 FY23** Q3 FY23** Q3 FY23** Q3 FY23** Q3 FY23** Q3 FY23** Q4 FY23** Q3 FY23** Q4 FY23**</td> <td>FY21 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23</td> <td>FY21 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 Q2 FY23 Q2 FY23 Q4 FY23 PY23 Q2 FY23 Q4 FY23 Q2 FY23 Q4 FY23 PY23 Q2 FY23 Q2 FY2</td> <td>FY21 FY22 Q1 FY23 Q2 FY23 Q4 FY23 PF23 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 FY21 1234 1234 1234 1234 1234 1234 1234 1234 1234 1234 1234 1234 1234 1234 1234 1234 1234 1234 602 602 602 527 527 334 334 334 334 3,064 975 975 975 1011 1011 1011 1011 602 602 602 527 527 250 250 250 250 250 2,599 875 875 875 911 911 911 911 484 484 484 418 195 195 195 195 226 2,590 100 100 100 100 100 110 118 118 118 109 109 55 55 55 55</td> <td>FY21 FY22 O1 FY23 Q2 FY23 Q4 FY23 FY23 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 PY24 FY23 Q2 FY23** Q3 FY23 Q4 FY23 PY24 FY23 FY24 FY23 Q2 FY23** Q3 FY23 Q4 FY23 Q4 FY23 PY24 FY23 PY24 <</td> <td>FY21 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 Q4 FY23 PY21 FY21 FY22 Q1 FY23 1234 1234 1234 1234 1234 1234 1234 1234 602 602 602 527 527 250 <td< td=""><td>FY21 FY22 O1 FY23 O2 F</td><td>FY21 FY22 1 FY23 02 FY23 02 FY23 03 FY23 04 FY23 02 FY23 03 FY23 04 FY23 FY23 02 FY23 03 FY23 04 FY23 FY23 02 FY23<td>FY21 FY22 1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 PY23 Q4 FY23 Q4 FY23<</td></td></td<></td>	FY21 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 1234 1234 1234 1234 1234 1234 602 602 602 527 975 975 975 1011 1011 1011 1011 602 602 602 527 875 875 875 911 911 911 911 484 484 484 418 100 100 100 100 100 118 118 118 109 766 746 603 758 723 760 711 191 206 171 165 87.5% 85.3% 69.0% 83.2% 79.3% 83.4% 78.8% 39.5% 42.6% 36.3% 39.6% 41,002 52,201 12,567 14,718 14,236 14,407 55,928 5,557 5,901 4,730 4,600	FY21 FY22 O1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 1234 1234 1234 1234 1234 1234 602 602 602 527 527 975 975 975 1011 1011 1011 1011 602 602 602 527 527 875 875 875 911 911 911 911 484 484 484 418 418 100 100 100 100 100 100 118 118 118 109 109 766 746 603 758 723 760 711 191 206 171 165 182 87.5% 85.3% 69.0% 83.2% 79.3% 83.4% 78.8% 39.5% 42.6% 36.3% 39.6% 39.5% 41,002 52,201 12,567 14,718 14	FY21 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 Q2 FY23** Q3 FY23 Q4 FY23 FY23 Q2 FY23** Q2 FY23** Q4 FY23 PY23 Q2 FY23** Q3 FY23 Q4 FY23 FY23 Q2 FY23*** Q2 FY23*** Q4 FY23 PY23 Q2 FY23*** Q3 FY23 Q4 FY23 PY23 Q2 FY23*** Q3 FY23 Q4 FY23 PY23 Q2 FY23*** Q3 FY23 Q4 FY23 PY23 Q3 FY23 Q4 FY23** PY23 Q3 FY23 Q4 FY23** Q2 FY23*** Q2 FY23*** Q3 FY23 Q4 FY23*** PY23 Q3 FY23** Q4 FY23*** Q2 FY23*** Q3 FY23*** Q4 FY23*** Q4 FY23*** Q4 FY23*** PY23*** Q4 FY23*** Q4 FY23***<	FY21 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 Q2 FY23* Q3 FY23 Q4 FY23 PY23 Q2 FY23** Q3 FY23** Q3 FY23** Q4 FY23 FY23 Q2 FY23** Q3 FY23** Q3 FY23** Q4 FY23** Q3 FY23** Q3 FY23** Q3 FY23** Q3 FY23** Q3 FY23** Q4 FY23** Q3 FY23** Q4 FY23**	FY21 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23	FY21 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 Q2 FY23 Q2 FY23 Q4 FY23 PY23 Q2 FY23 Q4 FY23 Q2 FY23 Q4 FY23 PY23 Q2 FY23 Q2 FY2	FY21 FY22 Q1 FY23 Q2 FY23 Q4 FY23 PF23 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 FY21 1234 1234 1234 1234 1234 1234 1234 1234 1234 1234 1234 1234 1234 1234 1234 1234 1234 1234 602 602 602 527 527 334 334 334 334 3,064 975 975 975 1011 1011 1011 1011 602 602 602 527 527 250 250 250 250 250 2,599 875 875 875 911 911 911 911 484 484 484 418 195 195 195 195 226 2,590 100 100 100 100 100 110 118 118 118 109 109 55 55 55 55	FY21 FY22 O1 FY23 Q2 FY23 Q4 FY23 FY23 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 FY23 PY24 FY23 Q2 FY23** Q3 FY23 Q4 FY23 PY24 FY23 FY24 FY23 Q2 FY23** Q3 FY23 Q4 FY23 Q4 FY23 PY24 FY23 PY24 <	FY21 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 Q4 FY23 PY21 FY21 FY22 Q1 FY23 1234 1234 1234 1234 1234 1234 1234 1234 602 602 602 527 527 250 <td< td=""><td>FY21 FY22 O1 FY23 O2 F</td><td>FY21 FY22 1 FY23 02 FY23 02 FY23 03 FY23 04 FY23 02 FY23 03 FY23 04 FY23 FY23 02 FY23 03 FY23 04 FY23 FY23 02 FY23<td>FY21 FY22 1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 PY23 Q4 FY23 Q4 FY23<</td></td></td<>	FY21 FY22 O1 FY23 O2 F	FY21 FY22 1 FY23 02 FY23 02 FY23 03 FY23 04 FY23 02 FY23 03 FY23 04 FY23 FY23 02 FY23 03 FY23 04 FY23 FY23 02 FY23 <td>FY21 FY22 1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 PY23 Q4 FY23 Q4 FY23<</td>	FY21 FY22 1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 PY23 Q4 FY23 Q4 FY23<


^{*}EBITDA before IND AS 116 and other income


^{1) **}Nagpur - For the month of September 2022 only


²⁾ Sunshine - All 3 locations (Karimnagar Unit sold in November 22 - included for 2 months in Q3 FY23 and not included in Q4 FY23

³⁾ AP Acquired Assets - Ongole, Vizag, Anantapur and Kurnool











*EBITDA before IND AS 116 and other income

- 1) Telengana Secunderad, Kondapur & Sushine 3 hospitals
- 2) AP Mature Nellore, Rajahmundry and Srikakulam
- 3) AP Non Mature Ongole, Vizag, Anantapur and Kurnool
- 4) Maharashtra Nagpur (7 months)







Key Achievements in Q4 FY23

58-year-old woman undergoes a complex surgery

- A team of doctors achieves a rare feet by performing Whipple procedure
- It takes seven hours to complete the complex surgery successfully

HANS NEWS SERVICE VISAKHAPATNAM

A 58-year-old patient suffering from periampullary carcinoma has undergone a complex surgery and was relieved of pain. The complex surgery was performed by Dr Prasad Yerra, consultant surgical gastroenterologist and his team at KIMS Icon hospitals in Visakhapatnam.

Sharing details of the operation, the doctor said, "Saraswathi was admitted to the hospital with primary complaints of weight loss, jaundice, and itching. She was diagnosed with periampullary carcinoma. If cancer spreads to the pancreatic, duodenum or distal common bile duct, ampullary carcinoma."

Since laparoscopic surgery for cancer-affected pancreas is compli-



Patient with the doctor at KIMS Icon Hospitals in Visakhapatnam

cated, the doctors performed Whipple (pancreaticoduodenectomy) procedure. The procedure took seven hours to complete successfully and the patient is now undergoing

Doctors said that such complex laparoscopic surgeries are very rare in Andhra Pradesh. So far, the hosthe condition is known as peripital has performed five laparoscopic Whipple pancreaticoduodenectomy surgeries in laparoscopic

12-year-old boy suffering from rare bleeding disorder treated

The Hindu Bureau HYDERABAD

Doctors of KIMS Hospital here performed a rare surgery on a 12-year-old boy suffering from incessant nose bleeding.

The boy is a native of Giddalur in Prakasam district of Andhra Pradesh. Initially, he was taken to local doctors in Giddalur, who gave him an injection. Two days later, the bleeding started again after which

the doctors performed a scan of his nose and found a tumour. The boy's parents were advised to take him to Hyderabad for further treatment.

Consultant ENT Surgeon at KIMS Hospital, C.Subramanyam said that a CT scan of the boy was conducted, after which they came to know it was due to a rare tumour called angiofibroma. "Angiofibromas appear normal but contain a lot of blood. As soon as

we touch the nose from outside, it starts bleeding. If we operate, the patient might lose 2-3 litres of blood and his life will be at stake. Usually, most doctors perform embolisation to prevent bleeding, but it is expensive," he said.

The KIMS doctors identified the point from where blood was being transmitted to the tumour and clamped the blood vessel. As a result, the bleeding was controlled.

Nurse from Zambia undergoes life saving surgery at KIMS

CITY BUREAU Hyderabad

A 36-year-old nurse from Zambia received a new lease of life after undergoing a life-saving surgery at city-based Krishna Institute of Medical Sciences (KIMS).

The nurse, who is a mother of three children, had undergone hysterectomy at the hospital where she was employed in Zambia. The surgery developed complications and her intestines were damaged in the process.

The nurse had undergone hysterectomy in Zambia but developed complications and was airlifted to Hyderabad

"She had undergone repeated surgeries, seven in all, to get the intestinal damage rectified and all of them failed. She became critical and was unable to eat food and was airlifted to Hyder-

abad," senior Surgical Gas troenterologist, KIMS hos pitals, Dr G. Parthasarathy said. In a 7-hour-surgery the injured intestines were sutured and some part: were removed as the infec tion had already spread Kept in ICU for 10 days, she recovered well and was able to eat normally and re gained her health com pletely, doctors said. The team of doctors include Dr M Sudheer, Dr. C Naresh Kumar Reddy HOD - Anes thesiology, Dr Ann Campo: ICU, and Dr Pavan – ICU.

Iraqi youth suffering from severe bowing of the knee

He has a congenital gene-related problemKIMS doctors correct with modern technology surgery

and brought up in Iraq, is a physical disability caused severe depression to him. He doesn't have proper medical facilities in his own country. The treatment cost in other major countries will cost a lot, which he can't bear. He is now 20 and came to know about the KIMShospitals of Hyderabad.He immediately came over here. Sajjad Ameen Matrood Alhasnawi, aged 20 has had a deformity of both lower limbs since childhood which and had difficulty walking. He was diagnosed to have epiphyseal dysplasia with severe genu valgus deformity (severe bowing of the knee) which is considered to be a sequel of rare congenital deformity. This

in very few patients the disease leads to severe deformities. Sajjad Ameen has a severe deformity in both limbs. Due to this issue, he had abnormal gait with difficulty daily living. He came to KIMS





(Taylor Spatial Frame) over 2- surgery. Now, Sajjad Ameen Srinivas Kasha, Dr Srinivas

done on him. We had to do the limbs was addressed si-surgeries can be done at an two different surgeries on him. multaneously. If left untreated, early age itself. If so, the youth These were done with ad- this disease would lead to de- would not have suffered all vanced deformity correction generative changes in the these years. These surgeries techniques using a computer joints, and the patient may can be done on anyone irrenavigated External fixator need early joint replacement spective of age" explained Dr

Advanced heart surgery performed at KIMS Ongole

HANS NEWS SERVICE ONGOLE

THE chief operating officer of KIMS Ongole K Ankireddy announced that their doctors performed an advanced heart surgery, for the first time in the Prakasam

Speaking at the press meet in Ongole on Friday, Ankireddy explained that an old man from Ravinuthala village was admitted to their hospital with symptoms of fatigue and vertigo. He said that the doctors diagnosed him as suffering from bradycardia, causing the heartbeat only 40 times a minute.

Dr Anand Yadav, the cardiac surgeon explained that in most cases, right ventricle of the heart, but about 15 percent of the pacemakers may not work as they should after a few years. Dr Anand said that as a solution to the problem of the patient, they decided to opt for Con-



of pacing to achieve more effective ventricular synchronization, and greatly improve cardiac function. He announced that this surgery was first time in their hospital.

The medical superintendent Dr T Srihari Reddy informed that the KIMS Ongole has the advanced systems to treat all types of cardiac electrophysiology diseases by per-

and radiofrequency ablation. He announced that their hospital provides quality medical services round the clock and advised the lo-

Ankireddy informed that the KIMS Hospital executive director T Giri Naidu appreciated the COO, the medical superintendent and the doctors' team and the supporting staff for successfully performing the



Key Achievements in Q4 FY23

लोकमत

किम्स-किंग्सवेमध्ये दुर्बीणने पित्तनलिकेवर शस्त्रक्रिया



लोकमत न्यूज नेटवर्क नागपूर : पित्ताशयात अडकलेली पथरी लेप्रोस्कोपिक सर्जरीद्वारे सहज काढली जाऊ शकते. मात्र, कधीकधी हे स्टोन ठरते. ५ ते १५ टक्के रुग्णांमध्ये असा प्रक्रिया ऑपरेशन न करता ईआरसीपी रुग्णांवर आले आहे.

तंत्रज्ञानाने पथरी सहज काढली जाऊ ऑपरेशन न करता यशस्वी उपचार करण्यात यश आले आहे. आंत रोग प्रकार होतो. मात्र, आता ही गूंतागूंतीची तज्ज्ञ डॉ. समीर पाटील यांनी अशा ८ नामक दुर्बिणीने सोपे करण्यात यश कोलैंजीओस्कोपीने यशस्वी उपचार केला आहे. पित्तनलिकेसाठीची ही

A 62-year-old woman was diagnosed with cancer when she consulted a doctor for ataxia

 KIMS Kurnool doctors identify with an antibody test. Detecting Breast Cancer in the first stage is very rare. Immediate treatment gives relief to the woman

plained of ataxia, which means imbalance while walking and also speech changes, after several tests, diagnosed with Breast Cancer in early stages!Detecting Breast Cancer with antibody tests is so rare. Doctors from KIMS hospital Kurnool detected the root cause and treated her. Jayamma, aged 62, who hails from Kurnool came to KIMS hospitals with the basic complaint of walking difficulty. She was unable to walk on her

port of two persons. She had speech changes and dizziness. Consultant Neurologist Dr. Nishanth Reddy tested her. He explained the case details. Based on her symptoms, an evaluation was started. When we did MRI Brain and other investigations didn't find any problem. Then, we went for a paraneoplastic profile test. Then Anti-Yo antibodies were positive. Our body's immune system produces some antibodies if some Cancer develops anywhere in the body. So, if the antibodies are present, we have to understand that Cancer is present in major in-



scan and came to know that she had breast mass. Immediately we referred the case to

performed the surgery, biopsy suggestive of breast carcinoma. Now she is undergoing Chemotherapy. Her symptoms have improved. Her speech improved. She can walk on her own with wall support, and can walk with one person's support when she comes out. Identifying cancer with antibodies is very rare. We can find only one or two per annum. She initially came to us with neuro problems. But, when we tried to find the root cause, then it came out to be cancer. Now she is improving explained Dr. Nishanth

పాపకు ప్రాణదానం

పుట్టుకతో తీవ్ర కామెర్లు.. పూర్తి రక్తమాల్పిడి చేసి కాపాడిన కిమ్మ్ కుడల్స్ వైద్యులు

సీతంపేట, ఫిబ్రవరి 2(ద్రభన్నూస్) : తల్లీ బిద్ధలకు ఒకటే గ్రూపు రక్తం ఉండి. అందులో పాజటివ్, నెగిటివ్ వేర్వరుగా ఉందటం వల్ల త్రీవస్తాయిలో పర్యకామెర్డు వర్స్, ప్రాణాపాయ సితిలో ఉన్న పాపకు విశాఖపట్నం కిమ్స్ కదల్స్ అస్సతి వైద్యులు పాజదానం చేశారు. అత్యంత అరుదుగా పూర్తిస్తాయి రక్షమార్చిడి చేయడం ద్వారా పాపను కాపాడగలిగారు. ఈ వివరాలను విశాఖపట్నం కిమ్స్ కడల్స్ అస్సతిలోని రీఫ్ నియోనాబాలజిస్టు, నియోనాబాలజీ విభాగాధిపతి డాక్టర్ నిఖిల్ తెన్నేటి వివరించారు. విశాఖపట్నంలోని గాజావాక ప్రాంతానికి చెందిన రియానా టేగం 38 వారాల గర్భం తర్వాత ఓ సుధుత్వాస్పుతిలో పాపకు జన్మనిద్చారు. తల్లి రక్షం ఓ నెగెటివ్ గ్రూపు, బిద్ద రక్షం ఓ పాజిటివ్ గ్రూపు ఉన్నాయి. ఈ కారణంగా పాపకు తీమ్రస్తాయిలో కామెర్డు వర్సాయన్నారు. బిడ్డ పుట్టిన 52 గంటలకు కిమ్స్ కడల్స్ అస్సుతికి తరలించారన్నారు. పరీక్షలు చేయగా, పాపకు బైలురూటిన్ ఏకంగా 36 మిట్టగామ్స్ పెర్ డెసీలీటర్ ఉంది. అది చాలా ఎక్కువ కావదంతో, మెదడు కూడా ద్రుభావితమై... పాప ఊపిరి పీల్చుకోలేకపోయిందన్నారు. అప్పుడప్పుడు ఫిట్స్ కూడా వర్సాయి. ప్రక్రియ దేశామన్నారు. అందులో భాగంగా పాప శరీరంలో ఉన్న మొత్తం రక్షాప్స్ తీసీసి, అదే గ్రూపులో కొత్త రక్షాన్ని ఎక్కించామన్నారు . దానివల్ల వెంటనే బ్రైలురూవిన్



నీయంతించగలిగామన్నారు. అతి తక్కువ సమయంలో వైలురూటిస్తో తగ్గించడం వ మైదరు సురక్షితంగా ఉందన్నారు. దానిపై ఎలాంటి స్థుభావం పదలేదన్నార సాధారణంగా ఒకే గూపులో తల్లీపిడలకు పాజిటివ్, నెగెటివ్ ఉంటే అప్పుడు త నుంచి విధకు యాంటీజాడీస్ వెళ్ళి, అవి విధ రక్షకుకాలపై దాడి చేస్తాయన్నార ఫలితంగా రక్షం పాదవుతుందన్నారు. అప్పుడు కామెర్గు పెరిగి, మైదడు కూర ద్రభావితమవుతుందన్నారు. పూర్తిగా వేర్వేరు గ్రహిషులు ఉంటే ఇబ్బంది లేదు గానీ, ఒ గ్రూపులో పాజిటివ్, నెగెటివ్ ఉంటే జలాంటి సమస్య వస్తుందన్నార భవిష్యత్తులోనూ ఈ పాపకు రక్షం తగ్గే స్రమాదం ఉంటుందన్నారు. అలాంటప్పు! అవసరమైతే మళ్లీ రక్తం ఎక్కిందాల్స్ ఉంటుందన్నారు. ఆ విషయాన్ని తల్లిదండుల కొన్నెలింగ్లో వివరించి, పాపను సంపూర్ణ ఆరోగ్యంతో డిశ్చార్థి చేశామన్నారు. శ చికిత్పలో డాక్టర్ సంతోష్ పాల్గొన్నారని డాక్టర్ నిఖిల్ తెన్నేటి వివరించారు.

Severely damaged femoral head and neck bone

KIMS Kurnool doctors cured with complex surgery

(Standard Post Bureau)

Kumool, Jan 9: KIMS Kurnool doctors have recently performed a complex surgery on Mr. Shair Rafiq, whose femoral head and neck bone was severely damaged in a road accident, and made him walk on his legs. Several



neck bones were badly Orthopaedic Consultants Kurnool have explained the neck got badly fractured.

doctors have rejected to damaged. But, KIMS Dr. P. Kiran Kumar and we examined the MRI and take up this case where doctors have successfully Dr.Ganesh Kumar Reddy CT Scan of the patient, his both femoral head and treated the young man. from KIMS hospitals hipjoint, Femoral head, and

"Shaik Rafig was seriously injured in a road accident. Though he consulted hospitals in different cities, no one agreed to take up the case given the seriousness of his accident. At last, they came to KIMS hospital in Kurnool. When

సమయానికి కారణం గుల్లంచి బతికించిన కిమ్మ్ ఐకాన్ వైద్యులు

విశాఖపట్నం, మార్చి28 మెట్రోవాయిస్ స్మూస్ : తెల్లవారుజామున కడుపునొప్పి, ఆ తర్వాత స్పృహ కోల్పోయిన రైతు.. దాదాపు బ్రెయిస్ ఇద్ పరిస్థితికి వెళ్లిపోయి, చివరకు కిమ్స్ ఐకాన్ ఆస్పత్రి వైద్యులు అందించిన చికిత్సతో ప్రాణాపాయం తప్పించుకున్నారు. వీశాఖ జిల్లా దోదవరం ప్రాంతానికి చెందిన 30 ఏళ్ల రైతు సమస్య, అందించి, చికిత్స తదితర వివరాలను విశాఖపట్నం కిమ్స్ ఐకాన్ ఇప్పుత్రికి చెందిన కన్సల్టెంట్ న్యూరో సర్జన్ డాక్టర్ సీహెచ్ విజయ్ కెలిపారు. "30 ఏళ్ల రైతుకు తెల్లవారుజామున 6 గంటల సమయంలో కదుపునాప్పి వచ్చింది. దాంతో స్థానికంగా ఉందే వైద్యుడికి చూపించగా, స్యానింగ్ చేయాలని చెప్పారు. ఆ సమయంలో స్మానింగ్ సాధ్యం కాదు కాబట్టి, ఇంటికి తీసుకెళ్లారు. రెండు గంటల తర్వాత ఊపిరి పీల్పుకోవడం కష్టమైపోయింది. క్రమంగా కాళ్లు, చేతులు బాగా సీరసించి కదలదం కష్టమైపోయింది. మనిషి అసలు బతికున్నాదో లేదో కూడా తెలియకపోవడంతో వెంటనే కిమ్స్ ఐకాన్ అన్ఫ[తికి తీసుకొచ్చారు. వచ్చేసరికి మనిషి దాదాపు కోమాలో ఉండటంతో పాటు కళ్లు తెరవడం లేదు. చేతులు కాళ్లు కదలడం లేదు. మాట సైతం లేదు. నాడి పరీక్షించగా అది కొట్టుకుంటోంది. దాంతో ప్రాణం ఉందని తెలిసి, వెంటనే ఊపిరి అందేందుకు వీలుగా వెంటిలేటర్ మీద పెట్టాం. న్యూరాలజీకి సంబంధించిన పరీక్షలు చేయగా, రోగి అంతర్గత స్థలు బాగానే ఉన్నట్లు తేలింది. కళ్లకు సంబంధించిన నరాలు పరీక్షిస్తే అవి స్పందించడం లేదు. ముఖంలోని నరాలు మాత్రం జాగానే ఉన్నాయి. శరీరం మీద పరీక్షిస్తే ఎక్కదా పాముకాటు లేదా తేలుకాటు రాంటి గుర్తులు కనిపించలేదు. కానీ అదే సమయంలో ఊపిరి బాగా బరువుగా తీసుకోవడం, గుండె నిమిషానికి 100 సార్లకు పైగా

సాధారణంగానే ఉన్నాయి. మెదడుకు, వెన్నెముకకు ఎంఆర్ఐ తీయగా. అవీ నార్మల్గానే వచ్చాయి. కానీ ఊపిరి మాత్రం నరిగా అందట్లేదు. అవి నార్మిలిగాన వచ్చాయి. కాని ఊపరి మాత్రం నరిగా అందట్టరు. వాంతో వెంటిలేటర్ కొనసాగించాల్సి వచ్చింది. న్యూరో చుస్మ్యులర్ జంక్షన్ సమస్యను పరిష్శరించాలని ఎట్రోసైన్, నియోస్టిస్నెన్ లాంటి మందులు ఇచ్చినా రైతు పరిస్టితి పెద్దగా మెరుగుపడలేదు. దాంతో అప్పుడు పాము విషం విరుగుడు మందు ఇచ్చాం. అప్పుడు నెమ్మదిగా కంటి చూపు విషయంలోను. కంటి పెరెపు కిందకి వాలిపోవడం



మిగిలిన అవయవాలను మెరుగుపరిచేందుకూ మందులు ప్రారంభించాం. ప్రతి ఆరు గంటలకు కాల్వియం గూకోనేట్ ఇచ్చాం మూడు రోజుల పాటు ఇంట్రావీనస్గా నియోస్టిగ్మైన్ కొనసాగించాం క్షామం రాజుల వాటు కంటావినినిగా నియ్యాగ్నిన కానినిగించార క్షమంగా ఊపిరి సాధారణ స్థితికి చేరుకుంది, కందరాల బలహీన తగ్గింది. ఏడో రోజున వెంటిలేటర్ తాలగించాం. ఆ తర్వాత కూడ కొన్ని సమస్యలు ఉండటంతో యాంటీఐయాటిక్స్తోలో చికిత్స చేశాం. క రైతుకు వచ్చిన సమస్యలన్నింది దృష్ట్రా చూస్తే, అతడికి కట్లపామ కాటినినట్లు భావించాం. పొలాల్లో తిరిగేటప్పుడు కాళ్లకు తగిన రక్షణ లేకపోవదం వల్ల ఇలాంటి కాట్లు పడే అవకాశం ఉంటుంది. కౌన్సిస్తార ంట్రీస్, కాలేయ పనితీరు పరీక్ష, మూత్రపిందాల పనితీరు పరీక్ష అన్నీ వల్ల వచ్చే ఇలాంటి సమస్యను ఎర్లీమార్నింగ్ పెరాలసీస్ అంటాం వెంటనే గుర్తించి తగిన చికిత్స అందించకపోతే రోగి క్రమంగ కోమాలోకి వెళ్లిపోయి ప్రాణాలు కోల్పోయే ప్రమాదం ఉంటుంది. ఎంగ విషపూరితమైన పాము కరిచినా, రెండు మూడు గంటల్లోగా అస్పత్రిలి చికిత్స మొదలైతే ప్రాణాలు కాపాడే అవకాశం ఉంటుంది. పాము కాట అని గుర్తించకపోయినా ఈ తరహా సమస్యలు వచ్చినప్పుడు వెంట వైద్యుల వద్దకు తీసుకెళ్లడం ముఖ్యం" అని దాక్టర్ సీహెచ్ విజయ్



Doctor Partnerships

Affordable Quality Care

Modern Medical Infra




KIMS has a disciplined growth strategy - strategically grow in adjacent markets some of which are 'natural extensions'

KIMS Plans to Grow into Markets that are Adjacent to the Current Core Markets of AP and Telangana

Central & Western India (Indore, Aurangabad, Nagpur & Raipur): KIMS flagship hospital witnesses influx of patients and doctors from Central India. Given scarcity of quality healthcare and existing KIMS brand awareness in Central India, smaller facilities can be set up in Central India

Karnataka (Bangalore and greater Karnataka):

KIMS has observed both cash patients and insurance patients traveling from the districts of AP bordering Karnataka to seek treatment at larger hospitals in Bangalore (Karnataka). Karnataka is a natural growth market because a sizeable portion of the state speaks Telugu - the main language spoken in AP and Telangana



Map not to scale



Profit and Loss Statement (Rupees in Millions)

				Conso	lidated			
Particulars	Q4 FY 23	Q3 FY 23	Q4 FY 22	QoQ(%)	YoY(%)	FY 23	FY 22	YoY(%)
Operating Revenue	5,759	5,622	3,723	2.4%	54.7%	21,977	16,508	33.1%
Other Income	49	64	82	-24.1%	-40.2%	259	203	27.7%
Total Revenue	5,808	5,686	3,805	2.1%	52.6%	22,235	16,711	33.1%
EBITDA *	1,563	1,444	1,127	8.3%	38.8%	5,766	5,122	12.6%
EBITDA (%) on operating revenue	27.1%	25.7%	30.3%			26.2%	31.0%	
PBT**	1,273	1,128	993	12.8%	28.1%	4,701	4,474	5.1%
PBT (%) on total revenue	21.9%	19.8%	26.1%			21.1%	26.8%	
PAT**	987	818	758	20.6%	30.2%	3,510	3,343	5.0%
PAT (%) on total revenue	17.0%	14.4%	19.9%			15.8%	20.0%	
Basic EPS(Rs.)	11.7	9.5	10.1	22.8%	15.6%	42.0	41.9	0.4%
Diluted EPS (Rs.)	11.7	9.5	10.1	22.8%	15.6%	42.0	41.9	0.4%
IND AS 116	69.0	67.9	9.3			273.6	35.4	

Minority share of EBITDA for FY23 stands at 12.4%

Private & Confidential

28

^{*}EBITDA before IND AS 116 and other income


^{**}PBT and PAT are excluding items of:

¹⁾ Associates share of profit of Rs. 19.7 Mn and Rs. 75.4 Mn in FY22 Q3 & Q4 and FY22

²⁾ Fair value gain on aquisition of control of Rs. 148.3 Mn in Q2 FY23 and FY23



Corporate Structure (As on 31st March'23)





Thank You